Aggressive Phenotype of Cells Disseminated Via Hematogenous and Lymphatic Route in Breast Cancer Patients

Overview

Journal Transl Oncol

Specialty Oncology

Date 2018 Apr 17

PMID 29660692

Citations 14

Authors

Aleksandra Markiewicz

Anna Nagel

Jolanta Szade

Hanna Majewska

Jaroslaw Skokowski

Barbara Seroczynska

Tomasz Stokowy

Marzena Welnicka-Jaskiewicz

Anna J Zaczek

Affiliations

Soon will be listed here.

Abstract

Intratumoral heterogeneity of breast cancer remains a major challenge in successful treatment. Failure of cancer therapies can also be accredited to inability to systemically eradicate cancer stem cells (CSCs). Recent evidence points to the role of epithelial-mesenchymal transition (EMT) in expanding the pool of tumor cells with CSCs features. Thus, we assessed expression level as well as heterogeneity of CSCs markers in primary tumors (PT), lymph node metastasis (LNM), and circulating tumor cells (CTCs)-enriched blood fractions in order to correlate them with signs of EMT activation as well as clinicopathological data of breast cancer patients. Level of CSCs markers (ALDH1, CD44, CD133, OCT-4, NANOG) and EMT markers was quantified in PT (N=107), LNM (N=56), and CTCs-enriched blood fractions (N=85). Heterogeneity of CSCs markers expression within each PT and LNM was assessed by calculating Gini Index. Percentage of ALDH1-positive cells was elevated in PT in comparison to LNM (P = .005). However, heterogeneity of the four CSCs markers: ALDH1 (P = .019), CD133 (P = .009), OCT-4 (P = .027), and CD44 (P < .001) was decreased in LNM. Samples classified as mesenchymal (post-EMT) showed elevated expression of CSCs markers (OCT-4 and CD44 in PT; OCT-4 in LNM; ALDH1, OCT-4, NANOG, CD44 in CTCs). Patients with mesenchymal-like CTCs had worse prognosis than patients with epithelial-like or no CTCs (P = .0025). CSCs markers are enriched in PT, LNM, and CTCs with mesenchymal features, but their heterogeneity is decreased in metastatic lymph nodes. Mesenchymal CTCs phenotype correlates with poor prognosis of the patients.

Citing Articles

Isolation of Viable Epithelial and Mesenchymal Circulating Tumor Cells from Breast Cancer Patients.

Topa J, Zaczek A, Markiewicz A Methods Mol Biol. 2024; 2752:43-52.

PMID: 38194026 DOI: 10.1007/978-1-0716-3621-3_3.

Improved Characterization of Circulating Tumor Cells and Cancer-Associated Fibroblasts in One-Tube Assay in Breast Cancer Patients Using Imaging Flow Cytometry.

Muchlinska A, Wenta R, Scinska W, Markiewicz A, Suchodolska G, Senkus E Cancers (Basel). 2023; 15(16).

PMID: 37627197 PMC: 10453498. DOI: 10.3390/cancers15164169.

Extraction, Characterization, and Evaluation of the Cytotoxic Activity of Piperine in Its Isolated form and in Combination with Chemotherapeutics against Gastric Cancer.

Ramos I, da Silva M, Lopes J, Cruz J, Alves F, Rego J Molecules. 2023; 28(14).

PMID: 37513459 PMC: 10385350. DOI: 10.3390/molecules28145587.

Correlation between mesenchymal circulating tumor cells and prognosis of urologic malignancies: a single-center retrospective analysis.

Wang L, Ding D Am J Transl Res. 2023; 15(1):502-510.

PMID: 36777844 PMC: 9908443.

Breast cancer circulating tumor cells with mesenchymal features-an unreachable target?.

Topa J, Gresner P, Zaczek A, Markiewicz A Cell Mol Life Sci. 2022; 79(2):81.

PMID: 35048186 PMC: 8770434. DOI: 10.1007/s00018-021-04064-6.

References

Markiewicz A, Ahrends T, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Jaskiewicz J . Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med. 2012; 10:226. PMC: 3524044. DOI: 10.1186/1479-5876-10-226. View

Beltran A, Rivenbark A, Richardson B, Yuan X, Quian H, Hunt J . Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res. 2011; 13(5):R94. PMC: 3262206. DOI: 10.1186/bcr3019. View

Oka M, Moriyama T, Asally M, Kawakami K, Yoneda Y . Differential role for transcription factor Oct4 nucleocytoplasmic dynamics in somatic cell reprogramming and self-renewal of embryonic stem cells. J Biol Chem. 2013; 288(21):15085-97. PMC: 3663529. DOI: 10.1074/jbc.M112.448837. View

Braun S, Naume B . Circulating and disseminated tumor cells. J Clin Oncol. 2005; 23(8):1623-6. DOI: 10.1200/JCO.2005.10.073. View

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D . Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65(13):5506-11. DOI: 10.1158/0008-5472.CAN-05-0626. View

Bruna A, Darken R, Rojo F, Ocana A, Penuelas S, Arias A . High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007; 11(2):147-60. DOI: 10.1016/j.ccr.2006.11.023. View

Chiou S, Wang M, Chou Y, Chen C, Hong C, Hsieh W . Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010; 70(24):10433-44. DOI: 10.1158/0008-5472.CAN-10-2638. View

Abourbih S, Sircar K, Tanguay S, Kassouf W, Aprikian A, Mansure J . Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study. World J Surg Oncol. 2013; 11:298. PMC: 3842840. DOI: 10.1186/1477-7819-11-298. View

10.

Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q . Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One. 2010; 5(4):e10277. PMC: 2858084. DOI: 10.1371/journal.pone.0010277. View

11.

Clarke M, Dick J, Dirks P, Eaves C, Jamieson C, Jones D . Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66(19):9339-44. DOI: 10.1158/0008-5472.CAN-06-3126. View

12.

Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S . Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2009; 27(13):2177-84. DOI: 10.1200/JCO.2008.18.0497. View

13.

Beerling E, Seinstra D, de Wit E, Kester L, van der Velden D, Maynard C . Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity. Cell Rep. 2016; 14(10):2281-8. PMC: 4802222. DOI: 10.1016/j.celrep.2016.02.034. View

14.

Luo W, Li S, Peng B, Ye Y, Deng X, Yao K . Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS One. 2013; 8(2):e56324. PMC: 3570418. DOI: 10.1371/journal.pone.0056324. View

15.

May C, Sphyris N, Evans K, Werden S, Guo W, Mani S . Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 2011; 13(1):202. PMC: 3109556. DOI: 10.1186/bcr2789. View

16.

Liu T, Sun B, Zhao X, Zhao X, Sun T, Gu Q . CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene. 2012; 32(5):544-53. DOI: 10.1038/onc.2012.85. View

17.

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

18.

Pantel K, Hayes D . Disseminated breast tumour cells: biological and clinical meaning. Nat Rev Clin Oncol. 2017; 15(3):129-131. DOI: 10.1038/nrclinonc.2017.174. View

19.

Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Shariftabrizi A . Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma. Exp Mol Pathol. 2017; 103(2):218-228. DOI: 10.1016/j.yexmp.2017.10.001. View

20.

Ito M, Shien T, Omori M, Mizoo T, Iwamoto T, Nogami T . Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor. Breast Cancer. 2015; 23(3):437-44. DOI: 10.1007/s12282-015-0583-1. View